Exane Derivatives Increases Stake in Alexion Pharm. (ALXN); Apple (AAPL) Holder First National Trust Co Lowered Position

April 20, 2018 - By Hazel Jackson

Apple Inc. (NASDAQ:AAPL) Logo

Exane Derivatives increased its stake in Alexion Pharm. (ALXN) by 48.58% based on its latest 2017Q4 regulatory filing with the SEC. Exane Derivatives bought 137 shares as the company’s stock declined 8.80% with the market. The institutional investor held 419 shares of the health care company at the end of 2017Q4, valued at $50.09 million, up from 282 at the end of the previous reported quarter. Exane Derivatives who had been investing in Alexion Pharm. for a number of months, seems to be bullish on the $24.85B market cap company. The stock decreased 1.08% or $1.22 during the last trading session, reaching $111.74. About 900,167 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 8.84% since April 20, 2017 and is downtrending. It has underperformed by 20.39% the S&P500.

First National Trust Co decreased its stake in Apple Inc (AAPL) by 1.65% based on its latest 2017Q4 regulatory filing with the SEC. First National Trust Co sold 2,273 shares as the company’s stock declined 3.81% with the market. The institutional investor held 135,291 shares of the computer manufacturing company at the end of 2017Q4, valued at $22.90M, down from 137,564 at the end of the previous reported quarter. First National Trust Co who had been investing in Apple Inc for a number of months, seems to be less bullish one the $876.79 billion market cap company. The stock decreased 2.83% or $5.04 during the last trading session, reaching $172.8. About 31.52M shares traded. Apple Inc. (NASDAQ:AAPL) has risen 19.49% since April 20, 2017 and is uptrending. It has outperformed by 7.94% the S&P500.

Analysts await Apple Inc. (NASDAQ:AAPL) to report earnings on May, 1 after the close. They expect $2.71 earnings per share, up 29.05% or $0.61 from last year’s $2.1 per share. AAPL’s profit will be $13.75 billion for 15.94 P/E if the $2.71 EPS becomes a reality. After $3.89 actual earnings per share reported by Apple Inc. for the previous quarter, Wall Street now forecasts -30.33% negative EPS growth.

Since December 7, 2017, it had 0 insider purchases, and 4 selling transactions for $19.89 million activity. Riccio Daniel J. sold $2.73 million worth of Apple Inc. (NASDAQ:AAPL) on Friday, January 5.

First National Trust Co, which manages about $909.31M US Long portfolio, upped its stake in Valero Energy Corp New (NYSE:VLO) by 11,241 shares to 66,378 shares, valued at $6.10 million in 2017Q4, according to the filing. It also increased its holding in Priceline Grp Inc (NASDAQ:PCLN) by 465 shares in the quarter, for a total of 1,133 shares, and has risen its stake in Ishares Tr (IVV).

Investors sentiment increased to 0.73 in 2017 Q4. Its up 0.03, from 0.7 in 2017Q3. It is positive, as 50 investors sold AAPL shares while 1023 reduced holdings. 151 funds opened positions while 637 raised stakes. 2.98 billion shares or 0.18% more from 2.97 billion shares in 2017Q3 were reported. Eulav Asset holds 0.27% or 34,000 shares. Carret Asset Mgmt Limited Liability Corporation holds 3.32% or 126,038 shares in its portfolio. Hayek Kallen Investment Management holds 46,116 shares or 5.12% of its portfolio. Shufro Rose Lc owns 75,746 shares for 1.26% of their portfolio. Ftb Advsr invested in 1.42% or 87,808 shares. Minneapolis Portfolio Management Gru Limited Company stated it has 0.1% of its portfolio in Apple Inc. (NASDAQ:AAPL). Parametrica Management invested 0.21% of its portfolio in Apple Inc. (NASDAQ:AAPL). Cohen Lawrence B accumulated 4.16% or 38,761 shares. Personal Cap Advisors stated it has 0.85% of its portfolio in Apple Inc. (NASDAQ:AAPL). Maryland Cap Management holds 3.81% in Apple Inc. (NASDAQ:AAPL) or 151,887 shares. Bluestein R H reported 4.57% in Apple Inc. (NASDAQ:AAPL). Horizon Svcs Limited Liability Corporation, a Indiana-based fund reported 48,573 shares. Northwestern Mutual Wealth Mgmt owns 625,621 shares. Reaves W H & reported 0.01% of its portfolio in Apple Inc. (NASDAQ:AAPL). Prudential Public Ltd Limited Liability Company owns 1.58% invested in Apple Inc. (NASDAQ:AAPL) for 3.08 million shares.

Among 54 analysts covering Apple Inc. (NASDAQ:AAPL), 35 have Buy rating, 1 Sell and 18 Hold. Therefore 65% are positive. Apple Inc. had 394 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Drexel Hamilton with “Buy” on Friday, October 27. The firm has “Overweight” rating given on Wednesday, October 28 by Piper Jaffray. The stock has “Outperform” rating by Credit Suisse on Thursday, September 15. The stock of Apple Inc. (NASDAQ:AAPL) has “Buy” rating given on Wednesday, July 5 by Nomura. The stock of Apple Inc. (NASDAQ:AAPL) has “Overweight” rating given on Wednesday, April 20 by Barclays Capital. RBC Capital Markets maintained the stock with “Buy” rating in Friday, September 11 report. On Wednesday, July 27 the stock rating was upgraded by Raymond James to “Outperform”. Brean Capital maintained Apple Inc. (NASDAQ:AAPL) rating on Monday, April 4. Brean Capital has “Buy” rating and $155 target. The firm earned “Outperform.” rating on Monday, October 26 by FBR Capital. The rating was maintained by Stifel Nicolaus on Wednesday, December 23 with “Buy”.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 104 analyst reports since July 27, 2015 according to SRatingsIntel. Nomura maintained it with “Buy” rating and $156 target in Monday, March 19 report. Morgan Stanley maintained the stock with “Overweight” rating in Tuesday, June 7 report. The firm earned “Market Perform” rating on Thursday, April 7 by BMO Capital Markets. UBS maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Friday, July 31. UBS has “Buy” rating and $223 target. The firm has “Outperform” rating given on Wednesday, September 13 by BMO Capital Markets. The firm earned “Buy” rating on Thursday, March 15 by Deutsche Bank. As per Wednesday, January 20, the company rating was initiated by Credit Suisse. The stock has “Buy” rating by Leerink Swann on Wednesday, December 6. The firm has “Outperform” rating by Raymond James given on Thursday, January 4. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Overweight” rating given on Thursday, May 25 by Morgan Stanley.

Investors sentiment decreased to 1.03 in Q4 2017. Its down 0.14, from 1.17 in 2017Q3. It is negative, as 65 investors sold ALXN shares while 171 reduced holdings. 64 funds opened positions while 178 raised stakes. 204.38 million shares or 1.21% less from 206.89 million shares in 2017Q3 were reported. Gabelli Funds Limited Liability Company holds 0.02% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 34,200 shares. Green Square Capital holds 0.06% or 3,485 shares. Rhenman Partners Asset Mgmt owns 151,863 shares for 2.45% of their portfolio. 419 are owned by Exane Derivatives. Lord Abbett Com Limited Liability Com invested 0.07% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Intrust Bancshares Na owns 2,483 shares. Highbridge Mgmt holds 0.38% or 176,173 shares. Raymond James Ser Advisors accumulated 27,435 shares. Mutual Of America Limited Liability Co owns 27,497 shares or 0.05% of their US portfolio. Art Advsrs Limited Com owns 75,800 shares for 0.4% of their portfolio. Point72 Asia (Hong Kong) holds 0% or 30 shares. Meeder Asset Mngmt invested in 0.05% or 4,596 shares. First Republic Invest Mgmt holds 0% or 2,242 shares. Pillar Pacific Capital Mgmt Limited Liability Co reported 0.27% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Ibm Retirement Fund invested in 0.12% or 5,444 shares.

Exane Derivatives, which manages about $580.60 billion US Long portfolio, decreased its stake in Coresite Realty (NYSE:COR) by 1,607 shares to 4,033 shares, valued at $459.20 million in 2017Q4, according to the filing. It also reduced its holding in Paypal Holdings by 118 shares in the quarter, leaving it with 31,807 shares, and cut its stake in Prologis (NYSE:PLD).

Apple Inc. (NASDAQ:AAPL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Hazel Jackson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: